FACULTY
Adil Daud, MD
Clinical Professor, Department of Medicine
(Hematology/ Oncology), UCSF
Director, Melanoma Clinical Research
UCSF Helen Diller Family Comprehensive
Cancer Center
San Francisco, CA
PROGRAM OVERVIEW
With multiple immunotherapy treatment options and combinations available for the management of advanced melanoma, clinicians require updates in the application of clinical data to guide shared decision making and multidisciplinary care. In this concise program, Dr. Adil Daud reviews current evidence-based guidelines, along with clinical data informing treatment decisions, and demonstrates best practices for their application in patients with advanced melanoma.
TARGET AUDIENCE
This activity is designed to meet the educational needs of oncologists, dermatologists, nurse practitioners, oncology pharmacists, and physician assistants who provide care for patients with advanced melanoma.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Describe evidence-based strategies for promptly screening and diagnosing melanoma early and the clinical signs of advanced disease
- Discuss the latest clinical evidence for LAG-3 and PD-1 inhibitors as immunotherapy for advanced melanoma
- Identify strategies for effective multidisciplinary care in managing advanced melanoma
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 0.5 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Adil Daud, MD | Research Funding: Bristol-Myers Squibb; Checkmate Pharmaceuticals; Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Merck/Schering Plough (Inst); Novartis; Oncosec (Inst); Pfizer (Inst) Consulting or Advisory Role: Genoptix; GlaxoSmithKline; Oncosec; Caris, Eisai, GLG Patents, Royalties, Other Intellectual Property – Trex, Oncosec Stock and other Ownership Interests: Neuvogen; Trex bio Honoraria: EMD Serono; Inovio Pharmaceuticals |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- Michael Milano, MD, discloses royalties from Wolters Kluwer.
- Michael R. Page, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services & Learner Engagement for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Amanda Jenkins, Program Manager for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager, has nothing to disclose.
- Melissa Johnson, Program Director for Med Learning Group, has nothing to disclose.
- Millena De Brito, Program Coordinator for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to the live event at [email protected]
RELEASED DATE: September 09, 2024
EXPIRATION DATE: September 09, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
